Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by SrPlataon Oct 16, 2021 7:22pm
130 Views
Post# 34014157

RE:No one knows about this company yet

RE:No one knows about this company yetYou are absoultley Right, Very Much under the Radar of individual investors, hence none of the popular individual forums for discussing stocks are to be found (except Stockhouse) WHY?

Here are my thoughts on Why

1. They have not done any public financings (so only a small number of investors)
2.  Arch has kept it quiet because they did not want fast money to come in. They know what they have and when time is right they will start the PR campaign to get the word out.
3. Shares are extremely tight very low volume hard to get in and out to flip.
4. Because no Wall st financings No Wall street analyst  research coverage
5 Some Biotech Investors are snooty, meaning if the company did not come from the Biotech Hub cities Like Boston, San Diego, Silicon Valley, then it probablly is not worth looking at. 

I'm sure there are a lot more reasons for the lack of investor ignorance on Arch, I truly believe that our time has come and we will finaly be "Discoverd" LOL 

Other thoughts or comments appreciated
<< Previous
Bullboard Posts
Next >>